Disease Transmitted Through Food Supply
The CDC recently published its annual update of infectious and communicable diseases that are transmitted through handling the food supply. Since the last publication of the list, on August 15, 1996, in the Federal Register, the CDC has received no further information to indicate that additional unlisted diseases are transmitted through handling the food supply. The contamination of raw ingredients from infected food-producing animals and crosscontamination during processing are more prevalent causes of foodborne disease than is contamination of foods by persons with infectious or contagious diseases. However, some pathogens frequently are transmitted by food contaminated by infected persons. 
Antiseptic-and Antimicrobial-Coated Catheters Reduce Bloodstream Infection Risk
Two recent studies published in the Annals of Internal Medicine provide additional evidence to support the clinical application of antiseptic or antimicrobial coating of central venous catheters (CVCs). The studies evaluated the predictors of catheter-related infections (catheter colonization and microbial colonization of the skin at the catheter insertion site) and assessed the impact of impregnated catheters in reducing the risk of catheter-related bloodstream infection.
Dr. Dennis Maki and colleagues recently conducted a randomized, controlled clinical trial in a medical-surgical intensive-care unit of a 450-bed university hospital to determine the efficacy of a noncuffed, multilumen CVC impregnated with chlorhexidine and silver sulfadiazine compared to a triple-lumen polyurethane catheter in preventing CVCVol. 18 No. 11 MEDICAL NEW related infection.
1 The antiseptic-impregnated catheter was associated with a 44% reduction in catheter colonization (13.5 compared with 24.1 colonized catheters per 100 catheters; P<.005) and a 79% reduction in the rate of catheter-associated bloodstream infections (1.0 compared with 4.7 infections per 100 catheters).
Use of these antiseptic catheters also was associated with a significant reduction in the number of organisms colonizing the skin around the catheter insertion site. No adverse effects from the antiseptic catheter were seen, and none of the 122 isolates obtained from infected catheters in either group showed in vitro resistance to chlorhexidinesilver sulfadiazine. Antiseptic catheters also showed comparable benefit with catheters placed into a new site and catheters placed into an old site over a guidewire.
Cost-benefit analysis indicated that the antiseptic catheter should prove cost-beneficial if an institution's rate of catheter-related bacteremia with noncuffed CVCs is at least three infections per 1,000 catheter days.
In a second study, Dr. Issam Raad and colleagues from the Texas Medical Center Catheter Study Group conducted a multicenter, randomized clinical trial comparing triplelumen polyurethane CVCs pretreated with tridodecylmethyl-ammonium chloride and coated with minocycline and rifampin to untreated, uncoated catheters.2 The use of treated or coated catheters also was associated with significant reductions in the rates of catheter colonization and catheter-related bloodstream infections (0 bloodstream infections per 1,000 catheter days compared with 7.34 bloodstream infections per 1,000 catheter days). The authors did not report the effect of the coated catheters in reducing colonization of the catheter insertion site.
An important finding in both of these studies was that none of the impregnated catheters was associated with adverse events (hypersensitivity or toxicity) or infections caused by resistant pathogens; however, additional evaluation still is needed. Both studies conclude that the use of impregnated catheters, although more expensive than traditional catheters, result in a net cost savings.
In an accompanying editorial, Dr. Michele Pearson of the CDC and Dr. Elias Abrutyn of the Allegheny University of Health Science, Philadelphia, point out that, because these two studies addressed only a subset of CVCs-tripldumen catheters-it remains to be determined whether the eco nomic benefit would persist if the use of impregnated catheters was expanded to include CVCs that are used more commonly and have a lower risk for infection (for example, peripherally inserted CVCs, single-lumen CVCs, or tunneled CVCs for long-term use).3 They also note the importance of other measures to reduce risk of catheter-related infections, including the use of maximal barrier precautions (sterile gloves, large sterile drape; sterile gown, cap, and mask) for insertion of CVCs and use of skilled personnel for insertion and maintenance. They conclude that technological advances are an important advance in reducing the rate of CVC-related infections; however, their use should be viewed as an adjunct to, rather than a substitute for, good aseptic practices 
Sepsis Varies With Patient Population
Sepsis syndrome is a leading cause of mortality in hospitalized patients. However, few studies have described the epidemiology of sepsis syndrome in a hospitalwide population. Researchers at the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School in Boston conducted a prospective, multiinstitutional observational study including 5-month follow-up to describe the epidemiology of sepsis syndrome in the tertiary-care hospital setting. Eight academic tertiary-care centers were used, and each center monitored a weighted random sample of intensive-care unit (ICU) patients, non-ICU patients who had blood cultures drawn, and all patients who received a novel therapeutic agent or who died in an emergency department or ICU. Sepsis syndrome was defined as the presence of either a positive blood culture or the combination of fever, tachypnea, tachycardia, clinically suspected infection, and any one of seven confirmatory criteria. Estimates of total cases expected annually were extrapolated from the number of cases, the period of observation, and the sampling fraction. From January 4, 1993, to April 2, 1994, 12,759 patients were monitored, and 1,342 episodes of sepsis syndrome were documented. The weighted estimate of haspitalwide incidence of sepsis syndrome was 2.0 cases per 100 admissions, or 2.8 per 1,000 patient days. The unadjusted attack rate for sepsis syndrome between individual centers differed by as much as threefold, but, after adjustment for institutional differences in organ transplant populations, variation from the expected number of cases was reduced to twofold and was not statistically significant overall. Patients in ICUs accounted for 59% of total extrapolated cases, non-ICU patients with positive blood cultures for 11%, and non-ICU patients with negative blood cultures for 30%. Septic shock was present at onset of sepsis syndrome in 25% of patients. Bloodstream infection was documented in 28%, with gram-positive organisms being the most frequent isolates. Mortality was 34% at 28 days and 45% at 5 months. It was concluded that sepsis syndrome is common in academic hospitals, although the overall rates vary considerably with the patient population. A substantial fraction of cases occur outside ICUs. The authors note that an understanding of the hospitalwide epidemiology of sepsis syndrome is vital for rational planning and treatment of hospitalized patients with sepsis syndrome, especially as new and expensive therapeutic agents become available.
